Vikram Purohit
Stock Analyst at Morgan Stanley
(0.74)
# 3,756
Out of 4,840 analysts
168
Total ratings
25%
Success rate
-14.5%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Downgrades: Equal-Weight | $73 → $62 | $54.54 | +13.68% | 7 | May 14, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $162.00 | +54.32% | 19 | May 5, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Equal-Weight | $10 → $8 | $4.08 | +96.08% | 2 | Apr 10, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $64.25 | +1.17% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $105.07 | +80.83% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $11.35 | +208.37% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.15 | +116.87% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $20.81 | +49.00% | 2 | Sep 11, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.66 | +163.16% | 1 | Jul 3, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $5.81 | +175.39% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.36 | +588.07% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $6.53 | +236.91% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $13.98 | -28.47% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $1.69 | +255.03% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.71 | +332.54% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $1.51 | +1,390.07% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $29.50 | +38.98% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $21.02 | +90.29% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $0.71 | +1,729.44% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $21.40 | +77.57% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.42 | +75.13% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $9.31 | +7.41% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $29.61 | -76.36% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.38 | +1,494.20% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $8.53 | +134.60% | 2 | Aug 5, 2020 |
Halozyme Therapeutics
May 14, 2025
Downgrades: Equal-Weight
Price Target: $73 → $62
Current: $54.54
Upside: +13.68%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $162.00
Upside: +54.32%
Recursion Pharmaceuticals
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $4.08
Upside: +96.08%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $64.25
Upside: +1.17%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $105.07
Upside: +80.83%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $11.35
Upside: +208.37%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.15
Upside: +116.87%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $20.81
Upside: +49.00%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.66
Upside: +163.16%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $5.81
Upside: +175.39%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $4.36
Upside: +588.07%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $6.53
Upside: +236.91%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $13.98
Upside: -28.47%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $1.69
Upside: +255.03%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.71
Upside: +332.54%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $1.51
Upside: +1,390.07%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $29.50
Upside: +38.98%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $21.02
Upside: +90.29%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $0.71
Upside: +1,729.44%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $21.40
Upside: +77.57%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.42
Upside: +75.13%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $9.31
Upside: +7.41%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $29.61
Upside: -76.36%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.38
Upside: +1,494.20%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $8.53
Upside: +134.60%